跳至主要内容
临床试验/NCT03770182
NCT03770182已完成不适用

Brain Stimulation for Neurological Patients

Storz Medical AG1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2017年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
1
主要终点
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) - Corrected Total Score

研究概览

简要总结

This is a prospective double-blind randomized placebo-controlled crossover clinical trial

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinically stable patients with probable Alzheimer's Disease (Diagnosis according to ICD-10 Criteria (F00))
  • At least 3 months of stable antidementive therapy or no antidementive therapy necessary
  • Signed written informed consent
  • Monthly pregnancy test for women in childbearing years
  • Age >= 18 years

排除标准

  • Non-compliance with the protocol
  • Pregnant or breastfeeding women
  • Relevant intracerebral pathology unrelated to the Alzheimers's disease (e.g. Brain tumor)
  • Hemophilia or other blood clotting disorders
  • Cortisone treatment within the last 6 weeks before first treatment
  • Thrombosis

结局指标

主要结局

Consortium to Establish a Registry for Alzheimer's Disease (CERAD) - Corrected Total Score

时间窗: month 3

CERAD stands for "The Consortium to Establish a Registry for Alzheimer's Disease". The CERAD was funded by the National Institute on Aging in 1986 to develop standardized, validated measures for the assessment of Alzheimer's disease (Fillenbaum 2008). CERAD is a cognitive test battery which is normalized for age, gender and education (Morris 1988). The CERAD total score (Chandler 2005) is a good measure for Alzheimer's Disease (Ehrensperger 2010, Rossetti 2010, Seo 2010, Hallikainen 2013). The CERAD total score is a scale from 0 to 100 with 100 meaning "normal cognitive ability" and 0 meaning "severe cognitive impairment".

次要结局

  • Alzheimer's Disease Assessment Scale (ADAS)(month 3)
  • Instrumental Activities of Daily Living Scale (IADL) - Patient(immediately post-treatment)
  • Leisure Behavior (FZV; German: Freizeitverhalten)([ Time Frame: month 3 ])
  • CERAD(month 3)
  • Neuropsychiatric Inventory (NPI) (Care Taker)(month 3)
  • Bayer Activities of Daily Living Scale (B-ADL)([ Time Frame: month 3 ])
  • Geriatric Depression Scale - short form (GDS-15)([ Time Frame: month 3 ])
  • anatomical Magnetic Resonance Imaging (MRI)(immediately post-treatment)
  • functional Magnetic Resonance Imaging (fMRI)(immediately post-treatment)
  • Neuropsychological Test Battery Vienna (NTBV)(month 3)
  • Beck Depression Inventory (BDI)(month 3)
  • IADL (Care Taker)(month 3)
  • Clock drawing test(month 3)
  • IADL- Patient(month 3)
  • Forgetfulness assessment inventory (FAI)(month 3)
  • Prosopagnosia index (PI20)(month 3)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验